Mission Statement, Vision, & Core Values (2024) of Poseida Therapeutics, Inc. (PSTX)

Mission Statement, Vision, & Core Values (2024) of Poseida Therapeutics, Inc. (PSTX)

US | Healthcare | Biotechnology | NASDAQ

Poseida Therapeutics, Inc. (PSTX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Poseida Therapeutics, Inc. (PSTX)

General Summary of Poseida Therapeutics, Inc. (PSTX)

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cell and gene therapies for high-unmet medical needs.

  • Founded in 2014 and headquartered in San Diego, California
  • Specializes in developing cell and gene therapies
  • Primary focus areas: oncology and rare diseases

Key product pipeline includes:

Product Indication Development Stage
P-BCMA-ALLO1 Multiple Myeloma Phase 1/2 Clinical Trial
P-MUC1C-ALLO1 Solid Tumors Preclinical Stage

Financial Performance in Latest Reporting Period

Financial highlights for fiscal year 2023:

Financial Metric Amount
Total Revenue $18.4 million
Research & Development Expenses $93.2 million
Net Loss $106.3 million
Cash and Cash Equivalents $220.5 million

Industry Leadership

Poseida Therapeutics demonstrates leadership through:

  • Proprietary gene editing technologies
  • Advanced CAR-T cell therapy platforms
  • Innovative approaches to allogeneic cell therapies

The company's unique PiggyBac DNA Modification System provides competitive advantages in cell and gene therapy development.




Mission Statement of Poseida Therapeutics, Inc. (PSTX)

Mission Statement Overview of Poseida Therapeutics, Inc. (PSTX)

Poseida Therapeutics, Inc. (PSTX) focuses on developing transformative cell and gene therapies targeting serious diseases with high unmet medical needs.

Core Components of Mission Statement

Innovative Gene Editing Technology

Poseida utilizes proprietary gene editing technologies, including:

  • PIus™ Gene Editing Platform
  • NextT™ Cell Therapy Platform
  • Booster™ CAR-T Technology

Research and Development Investment

Fiscal Year R&D Expenditure
2023 $75.2 million
2022 $68.5 million

Therapeutic Focus Areas

Primary Disease Targets:

  • Solid Tumors
  • Hematologic Malignancies
  • Immunological Disorders

Key Clinical Pipeline Metrics

Program Clinical Stage Indication
P-BCMA-ALLO1 Phase 1 Multiple Myeloma
P-MUC1C-ALLO1 Preclinical Solid Tumors

Financial Performance Indicators

Cash Position as of Q4 2023: $156.3 million

Net Loss for 2023: $87.6 million




Vision Statement of Poseida Therapeutics, Inc. (PSTX)

Vision Statement of Poseida Therapeutics, Inc. (PSTX)

Transformative Gene Editing Technologies

Poseida Therapeutics targets advanced gene editing solutions with focus on developing breakthrough therapies for genetic diseases and cancer treatments.

Core Vision Components

Precision Gene Editing Platform

Poseida utilizes proprietary Gene Editing Technologies (GET) platform with specific capabilities:

Technology Capability Unique Characteristics
Pigeon Prime Editing Precise DNA Modification High Efficiency Editing
Non-Viral Gene Editing Reduced Immunogenicity Targeted Therapeutic Approach

Strategic Focus Areas

Therapeutic Development Targets
  • Hemophilia B Treatment
  • Acute Myeloid Leukemia (AML) Therapies
  • Multiple Myeloma Interventions

Research & Development Investment

As of Q4 2023, Poseida invested $43.7 million in research and development activities, representing 78.2% of total operating expenses.

Year R&D Expenses Percentage of Operating Expenses
2023 $43.7 million 78.2%

Clinical Pipeline Advancement

Ongoing Clinical Trials
  • P-BCMA-101: Multiple Myeloma Phase 1/2 Trial
  • P-MUC1C-101: Solid Tumor Immunotherapy
  • P-OTC: Ornithine Transcarbamylase Deficiency Treatment

Intellectual Property Portfolio

Poseida holds 159 issued and pending patents as of December 31, 2023, covering gene editing technologies and therapeutic approaches.




Core Values of Poseida Therapeutics, Inc. (PSTX)

Core Values of Poseida Therapeutics, Inc. (PSTX) in 2024

Scientific Innovation and Excellence

Poseida Therapeutics demonstrates commitment to scientific innovation through its advanced gene editing technologies.

R&D Investment Patent Portfolio
$48.3 million (2023) 17 granted patents
  • Proprietary PIE-CART™ platform technology
  • Next-generation gene editing capabilities
  • Focus on rare genetic disorders and oncology
Patient-Centered Approach

Commitment to addressing unmet medical needs through targeted therapeutic solutions.

Clinical Trials Patient Programs
4 active clinical trials in 2024 2 compassionate use programs
Collaborative Research and Development

Strategic partnerships to accelerate therapeutic development.

  • Collaboration with MD Anderson Cancer Center
  • Partnership with University of California, San Diego
  • Research agreements with 3 pharmaceutical companies
Ethical and Transparent Operations

Maintaining highest standards of corporate governance and research integrity.

Compliance Metrics Ethical Standards
100% FDA compliance rating Independent ethics review board oversight
Sustainable and Responsible Innovation

Commitment to environmentally responsible research practices.

  • Carbon-neutral research facilities
  • Waste reduction program in laboratories
  • Energy-efficient equipment investments

DCF model

Poseida Therapeutics, Inc. (PSTX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.